Tetrahedral Framework Nucleic Acid-Puerarin Complex Alleviates Osteoporosis Through the FXR/Runx2 Axis

Area of Science:

• Biomaterials Science
• Nanotechnology
• Pharmacology

Background:

• Osteoporosis treatment faces challenges with current anti-osteoporosis medications due to administration inconvenience and side effects.
• Puerarin (Pue) shows therapeutic potential for osteoporosis but suffers from poor solubility, low bioavailability, and instability, limiting its clinical application.

Purpose of the Study:

• To synthesize and characterize a novel nanocomplex for enhanced puerarin delivery.
• To evaluate the therapeutic potential of the puerarin-loaded nanocomplex for osteoporosis treatment.

Main Methods:

• Synthesis of a tetrahedral framework nucleic acids(tFNAs)-puerarin complex (TPC).
• In vitro and in vivo evaluation of TPC's cellular uptake, stability, osteogenic activity, and anti-osteoporosis effects.
• Investigation of the underlying molecular mechanisms, including the FXR/Runx2 pathway.

Main Results:

• The synthesized TPC exhibited enhanced cellular uptake and stability compared to puerarin alone.
• TPC demonstrated superior osteogenic activity and significant anti-osteoporosis effects.
• The therapeutic benefits of TPC were found to be mediated through the FXR/Runx2 pathway.

Conclusions:

• The novel TPC nanocomplex represents a promising advancement in osteoporosis therapy.
• TPC overcomes the limitations of puerarin, offering improved efficacy and stability.
• This study highlights the potential of nanocarrier systems for enhancing the therapeutic properties of natural compounds for osteoporosis.